Adia Med Inc. sold a 30% interest in its Adia Labs division to Live Oak Health, a stem cell distributor, for $1.5 million, including $1 million in cash and a $500,000 promissory note. The deal also includes a two-year option for Live Oak Health to buy an additional 10% stake for $500,000. As part of the agreement, Live Oak Health will become an exclusive distributor of Adia Labs products through its existing sales force, expanding Adia Labs' market reach without building internal distribution. Adia Med retains 70% ownership and benefits from the cash infusion and partnership to grow its regenerative medicine product sales.
The Adia Med partnership and stake sale provide context for health sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 06, 2026 19:45 WIB: out of 100 priced US health-sector stocks, 67 rose and 24 fell. Among notable movers, DNA (Ginkgo Bioworks Holdings Inc) rose 3.54% to USD 15.51 with a typical hold time of 8 days and a nearly balanced buy-sell order split, while FLNA (Cassava Sciences Inc) gained 3.45% to USD 0.90 with a much longer hold time of 37 days and a strong buy bias at 92%. BBIO (BridgeBio Pharma Inc) increased 3.11% to USD 68.20, held typically for 63 days, with exclusively buy orders on Pluang.
Morgan Stanley analyst Bob Huang lowered American International Group's (AIG) price target to $80 from $81, with the stock trading around $76, indicating potential upside. AIG is set to report its Q3 2026 earnings on November 3, with investors focuse...
Vertiv Holdings, a maker of power and cooling equipment for data centers, faces mixed analyst opinions with GLJ Research rating it a "Sell" and BMO Capital giving an "Outperform" rating. Despite a recent stock pullback, the company reported a 241% in...
Apogee Enterprises reported strong fiscal Q2 results with adjusted earnings of $1.17 per share, nearly double the estimated $0.59, and revenue of $391.14 million, surpassing expectations of $362.6 million. This marks a continued trend of beating esti...
McKesson received a bullish price target of $977 from Morgan Stanley, suggesting a 6.7% upside from its current price of $915.45. The company agreed to acquire Option Care Health for $32.05 per share, valuing the deal at approximately $5.8 billion in...
Ameriprise Financial has authorized an additional $5.5 billion for share repurchases through September 2028, supported by $2.1 billion in excess capital and $2.8 billion in liquidity. The company returned $1.9 billion to shareholders in H1 2026, incl...
